Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Terramicina** is a prescription topical fixed-dose antibacterial ointment containing oxytetracycline hydrochloride and polymyxin B sulfate. Oxytetracycline is a tetracycline antibiotic that reversibly binds the bacterial 30S ribosomal subunit and inhibits aminoacyl-tRNA binding, suppressing bacterial protein synthesis; polymyxin B binds bacterial membrane lipopolysaccharide and disrupts membrane integrity. The Farmasierra product contains 30 mg/g oxytetracycline hydrochloride and 10,000 IU/g polymyxin B sulfate and is applied to treat superficial skin infections caused by susceptible bacteria. ([cima.aemps.es](https://cima.aemps.es/cima/dochtml/ft/19650/FT_19650.html))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxytetracycline + polymyxin B.